Dr. Riess is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2279 45th St
Sacramento, CA 95817Phone+1 916-734-5959Fax+1 916-703-5265
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2009 - 2012
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
Rutgers Robert Wood Johnson Medical SchoolClass of 2006
Certifications & Licensure
CA State Medical License 2008 - 2026- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Start of enrollment: 2018 Jun 26
- Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Start of enrollment: 2019 Apr 16
- Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer Start of enrollment: 2020 Oct 26
Publications & Presentations
PubMed
- 439 citationsFive-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%Martin Reck, Delvys Rodriguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csőszi
Journal of Clinical Oncology. 2021-04-19 - 57 citationsProlonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.Jonathan W. Riess, Seema Nagpal, Michael, Michael Zeineh, Matthew A. Gubens
Clinical Lung Cancer. 2014-05-01 - 40 citationsComutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.Marcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave
Cancer Discovery. 2023-07-07
Press Mentions
Commentary: Genetic Components of NSCLC, June 2022June 1st, 2022- Clinical Edge Journal Scan Commentary: Lung Cancer May 2022May 3rd, 2022
- The White Ribbon Project Comes to Cancer Center to Shine Light on Deadliest of CancersAugust 25th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
